

# The relations between location and outcome in stereotactic neurosurgery for drug abuse

<b>Submission date</b> 19/01/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 17/02/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 17/02/2011	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Guodong Gao

**Contact details**  
1# Xinsi Road, Baqiao District.  
Xi'an  
China  
710038

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
2007BAI0703

## Study information

**Scientific Title**

A randomised blinded trial of nucleus accumbens ablation to treat opiate dependence in humans: location correlates with outcome

### **Study objectives**

Surgical interventions within the nucleus accumbens are reported to have variable rates of efficacy and complications for a range of neuropsychiatric illnesses. We hypothesize that slight variations in lesion location may have an important influence on clinical outcome. To investigate the optimal lesion site, we established a prospective randomised double-blinded trial to analyze opiate abstinence and complication rate in different radiofrequency ablation lesion locations within the nucleus accumbens (NAc).

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethics Committee of Fourth Military Medical University approved on the 15th October 2003.

### **Study design**

Randomised single centre prospective double-blinded interventional clinical trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

### **Health condition(s) or problem(s) studied**

Functional neurosurgery for drug addiction

### **Interventions**

1. Radiofrequency ablation of the NAc
2. Different lesioning location and volume within NAc in four groups
3. Abstinence from opioid use and adverse events related to operation
4. Neuropsychiatric functional changes, measured by formal neuropsychiatric instruments

Follow up length: 4 years

### **Intervention Type**

Procedure/Surgery

### **Phase**

Not Applicable

**Primary outcome measure**

Abstinence from opioid use, measured by morphine urinalysis and naloxone testing in the fourth post-operative year

**Secondary outcome measures**

1. Complications in stereotactic surgery (e.g fever, nausea/emesis, seizure, infection, intracranial haemorrhages)
2. Possible neuropsychiatric change related to NAc ablation: memory, motivation, emotion, olfactory sensation

After operation, the secondary outcomes were measured at six month intervals and extended for four years.

**Overall study start date**

01/01/2004

**Completion date**

30/11/2004

## Eligibility

**Key inclusion criteria**

1. Heroin abuse using 0.3 - 1.0 g daily for at least 3 years by intravenous injection with or without concomitant nasal inhalation
2. Failure of multiple other treatment modalities
3. Ages between 18 and 50 years, either sex
4. Completion of detoxification treatment preoperatively with no somatic symptoms of withdrawal and negative morphine urinalysis and naloxone tests

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

80

**Key exclusion criteria**

1. Inability to give informed consent
2. Human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) virus carrier

3. Developmental delay, cognitive impairment, personality disorders and neuropsychiatric diseases other than addiction

**Date of first enrolment**

01/01/2004

**Date of final enrolment**

30/11/2004

## **Locations**

**Countries of recruitment**

China

**Study participating centre**

**1# Xinsi Road, Baqiao District.**

Xi'an

China

710038

## **Sponsor information**

**Organisation**

Ministry of Science and Technology (China)

**Sponsor details**

15B Fuxin Road

Beijing

China

100862

**Sponsor type**

Government

**Website**

<http://www.most.gov.cn/>

**ROR**

<https://ror.org/027s68j25>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

Ministry of Science and Technology (China) (ref: 2007BAI0703)

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration